| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lifecore Biomedical, Inc.$4.48
+0.16 (+3.69%)
0Pipeline Score Tools & Services · Pre-Clinical
Market Cap
184.92 M
EPS
-
P/E Ratio
-
Value Trade
2.28 M
SEC Financials
Q1 2026Dilution Risk
Revenue
23.19 M
R&D Expenses
1.22 M
Operating CF
4.70 M
Total Assets
225.50 M
Total Liabilities
204.72 M
Equity
-28.44 M
D/E Ratio
12,345
9.56 %
Week
-6.27 %
1 Month
-31.34 %
3 Month
-33.11 %
6 Month
-59.24 %
5 Year
-61.33 %
All Time
Cash Data
Cash Position
20.80 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
4.79 K
52 Week Range
3.63 - 8.98
% held by Insiders
9.7 %
% held by Institutions
71.94 %
Enterprise Value
363.48 M
Total Shares
37.53 M
Short %
10.23 %
Float Shares
24.24 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lifecore Biomedical, Inc.
142Total events
2Upcoming
29Tier-1 (high impact)
2012 – 2028Coverage
Upcoming catalysts 2
TBD
T2Product Launch
Subscribe to view catalyst details
TBD
T3Manufacturing Milestone
Subscribe to view catalyst details
Event history 2
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
TBD
◆R&D DayPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 0%
Micro Cap (rank 914 of 913)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LFCR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LFCR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LFCR▲ +3.7%today
Lifecore Biomedical Signs Three New Customer Agreements
Lifecore Biomedical has signed three new customer agreements, enhancing its pipeline of early- and late-stage programs. One agreement focuses on a late-stage development program in regenerative medicine, while the other two involve early-stage projects with a global medical technology company. These agreements are anticipated to contribute to Lifecore's revenue by 2028, reflecting the company's growth strategy.
Read more →LFCRQuality to the Core: A Conversation with Patrick Curran
The article features a conversation with Patrick Curran, Warehouse Manager at Lifecore, highlighting the importance of quality management in logistics operations. Lifecore's commitment to quality is evident through their rigorous inventory management and compliance processes. The company prioritizes precision and documentation over speed, ensuring that manufacturing remains uninterrupted by material shortages.
Read more →LFCRLifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
Lifecore Biomedical has signed a new agreement with a global pharmaceutical company to support the commercial production of an injectable suspension product for neurological disorders. This agreement marks the seventh addition to Lifecore's late-stage pipeline in just seven months, showcasing the company's growing momentum and expertise in specialized manufacturing. CEO Paul Josephs emphasized the confidence in Lifecore's capabilities and the increasing demand for complex pharmaceutical products.
Read more →LFCR▲ +12.4%on this news
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
Lifecore Biomedical has signed a manufacturing services agreement with a prominent ophthalmic disease management provider. This agreement involves process development and technical transfer for a next-generation injectable product. It marks the sixth addition to Lifecore's late-stage pipeline in just seven months, highlighting the company's growth strategy in the ophthalmic injectables sector.
Read more →LFCRQuality to the Core: A Conversation with Jeremy Huotari
The article features an interview with Jeremy Huotari, a Staff Project Manager at Lifecore, discussing the critical role of cleanroom design in pharmaceutical manufacturing. Huotari highlights how quality management is integrated into facility design, emphasizing that every decision impacts product quality and patient safety. His extensive experience provides insights into maintaining cleanrooms while production continues.
Read more →LFCR▲ +9%on this newsshared move
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference
Lifecore Biomedical, a contract development and manufacturing organization, has announced its participation in the upcoming William Blair 46th Annual Growth Stock Conference. The event is scheduled for June 2-4, 2026, in Chicago, Illinois. Key executives from Lifecore, including CEO Paul Josephs and CFO Ryan Lake, will attend and engage in investor meetings. This participation highlights Lifecore's commitment to attracting investor attention and fostering relationships within the biopharmaceutical sector.
Read more →LFCRLifecore Biomedical to Participate at CDMO Live Europe
Lifecore Biomedical, Inc. will participate in the upcoming CDMO Live Europe conference scheduled for May 19-21, 2026, in Rotterdam, Netherlands. The company, known for its capabilities in the development and manufacturing of sterile injectable products, invites interested parties to arrange meetings during the event. Lifecore has a strong reputation in the industry, particularly in producing injectable-grade hyaluronic acid.
Read more →LFCRLifecore Biomedical Reports Financial Results for the First Quarter Ended
Lifecore Biomedical, Inc. announced its financial results for the first quarter ending March 31, 2026, reporting a 34% decrease in revenue compared to the prior year. Despite the revenue drop, the company reaffirmed its 2026 financial guidance, highlighting successful execution of new commercial contracts and cost containment initiatives that led to a 52% reduction in operating expenses. The firm saw its gross profit margin decline to 19% and an increase in net loss year-over-year. Lifecore's conference call will discuss these developments and their strategic outlook.
Read more →LFCRLifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026
Lifecore Biomedical, Inc. is set to report its financial results for the first quarter of 2026 on May 6, 2026, before market opening. The company's senior management will host a webcast at 8:00 a.m. Eastern Time on that day to discuss the results. Investors and interested parties can access the live and archived webcasts through Lifecore's Investor Events & Presentations page.
Read more →LFCRLifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical, Inc. announced the grant of a restricted stock unit (RSU) award of 5,000 shares to a newly hired employee as part of its Equity Inducement Plan. This grant, effective April 20, 2026, was approved by the company's compensation committee and serves as an incentive for the employee to join Lifecore. The RSUs will vest on the third anniversary of the grant date, contingent upon continued employment.
Read more →LFCRLifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
Lifecore Biomedical, Inc. (LFCR) will participate in the 12th Annual American Biomanufacturing Summit scheduled for April 14-15, 2026, in San Francisco, CA. The company aims to discuss its expertise in process development and manufacturing services for injectable pharmaceutical products. This participation underscores Lifecore's position as a key player in the CDMO sector.
Read more →LFCR▼ -5.4%on this news
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 26, 2026
Lifecore Biomedical announced the granting of 18,500 restricted stock units (RSUs) to a newly hired employee as part of its Equity Inducement Plan. This award, approved by the compensation committee, is intended to incentivize the new hire's commitment to the company. The RSUs will vest after three years, contingent on continued employment.
Read more →LFCR▼ -7.6%on this newsshared move
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
Lifecore Biomedical has signed two new manufacturing agreements with an existing U.S. biopharmaceutical customer. One agreement involves a commercial site transfer for a marketed product, while the other expands manufacturing capabilities to a new delivery system. These agreements are expected to enhance Lifecore's revenue potential by 2028 and reflect the company's successful commercial strategy.
Read more →LFCRLifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
Lifecore Biomedical has entered into a commercial manufacturing agreement with a leading aesthetics company for an established product. This marks the third such agreement in five months, reflecting the company's strategic focus on late-stage programs. The partnership is anticipated to generate revenue within 24 months, contributing to Lifecore's projected growth through 2029.
Read more →LFCR▼ -33.3%on this news
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended
Lifecore Biomedical reported strong financial results for the fourth quarter and transition period ending December 31, 2025, with revenues reaching $35.7 million and an overall growth of 20% year-over-year. The company signed five new programs during this period, highlighting its expansion efforts. Although the company projects significant revenue growth for 2026, it also anticipates a net loss and faces risks from customer changes and delays in product launches. Lifecore aims for continued improvement in EBITDA margins and revenue growth through strategic initiatives and customer diversification.
Read more →LFCR▼ -33.3%on this news
Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating Lifecore Biomedical on behalf of its investors following a report of significant losses. The company's Q4 2025 financial results revealed a projected revenue drop to between $120 million and $125 million, compared to $141.4 million in the previous year. This decline has been driven by operational issues such as customer loss and delays in product launches, leading to an 18% stock price drop. Investors impacted by these events are encouraged to reach out to Johnson Fistel for potential recovery of losses.
Read more →LFCRLifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
Lifecore Biomedical, Inc. will participate in the 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum scheduled for March 17-18, 2026. Mr. Josephs, a key figure at Lifecore, will be a featured speaker in a fireside chat, offering insights into the company's operations. Additionally, Lifecore management will engage in investor meetings during the event. This forum serves as a platform for Lifecore to connect with potential investors and highlight its expertise in injectable pharmaceutical products.
Read more →LFCRLifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
Lifecore Biomedical, Inc. has announced it will report its financial results for the fourth quarter and transition period ended December 31, 2025, on March 16, 2026. The report will be available before market opening, followed by a webcast at 8:30 a.m. Eastern Time featuring senior management discussing the results. The archived version of the webcast will be accessible on Lifecore's website for 30 days, emphasizing the company's commitment to communication with stakeholders.
Read more →LFCRLifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
Lifecore Biomedical has signed a new agreement with Indomo to support the development of DT-001, a corticosteroid drug for treating inflammatory acne. Lifecore will manufacture clinical batches of the drug to facilitate its advancement into Phase 2 clinical trials scheduled for 2026. The partnership aims to enhance patient access to effective acne treatments through the innovative ClearPen device.
Read more →LFCRLifecore Biomedical to Participate at DCAT Week 2026
Lifecore Biomedical, a contract development and manufacturing organization, will participate in DCAT Week 2026, scheduled for March 23-26 in New York City. The event provides an opportunity for Lifecore to connect with industry professionals and showcase its capabilities in sterile injectable products. The company emphasizes its extensive experience in supporting biopharmaceutical innovations.
Read more →LFCRLifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
Lifecore Biomedical, Inc. announced the approval of inducement grants under Nasdaq Listing Rule 5635(c)(4) for two newly hired employees. The grants include restricted stock units and stock options, aimed at incentivizing talent acquisition. The RSUs will vest after three years, while the stock options have a structured vesting schedule over seven years.
Read more →LFCRLifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical, Inc. announced the approval of equity inducement grants for two newly hired employees under its Equity Inducement Plan. The grants include restricted stock units and stock options totaling 10,513 shares, which will vest over time, subject to employment continuity. This initiative reflects Lifecore's growth strategy and commitment to attract talent while adhering to Nasdaq regulations.
Read more →LFCRLifecore Biomedical to be Added to Nasdaq Biotech Index
Lifecore Biomedical, Inc. has been notified by Nasdaq of its inclusion in the Nasdaq Biotech Index, effective December 22, 2025. This announcement reflects the company's compliance with eligibility criteria such as market capitalization and trading volume. Lifecore is recognized for its expertise in contract development and manufacturing, particularly in sterile injectable pharmaceutical products. The Nasdaq Biotech Index aims to track the performance of significant biotechnology and pharmaceutical companies listed on Nasdaq.
Read more →LFCR▲ +9.9%on this newsshared move
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer
Lifecore Biomedical has signed a CDMO master services agreement with a new large multinational pharmaceutical customer. This agreement involves development services and tech transfer for an injectable product, aiming to transition commercial supply to Lifecore's facilities. The new partner has the potential to become one of Lifecore's top five customers, highlighting the company's growing business momentum.
Read more →LFCRLifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference
Lifecore Biomedical, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12-15, 2026, in San Francisco. As a contract development and manufacturing organization, Lifecore specializes in sterile injectable products and has over 40 years of industry experience. This participation highlights the company's commitment to innovation in biopharmaceuticals.
Read more →LFCR▲ +6.2%on this news
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical, Inc. will participate in two investor conferences from November 17-20, 2025. CEO Paul Josephs will present a corporate overview and engage in investor meetings in London, followed by a fireside chat in Nashville. Webcasts of these events will be available on Lifecore's investor website.
Read more →LFCRLifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update
Lifecore Biomedical reported a 26% increase in revenue for the three months ended September 30, 2025, totaling $31.1 million. The company highlighted improvements in efficiency and productivity, along with a positive outlook for future growth. However, it also reported a net loss of $10 million, attributed to increased interest expenses and lower development revenue. Lifecore aims for a revenue CAGR of over 12% and improved EBITDA margins in the coming years.
Read more →LFCRLifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025
Lifecore Biomedical, Inc. will report its financial results for the three months ended September 30, 2025, on November 6, 2025, after market close. A webcast is scheduled for that day at 4:30 p.m. Eastern Time, where the management team will discuss the results. Lifecore specializes in contract development and manufacturing for sterile injectable products and boasts over 40 years of experience in this sector.
Read more →LFCRLifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
Lifecore Biomedical has been selected as the new commercial manufacturing partner for a leading global pharmaceutical company, marking its second agreement with this organization in recent months. This site transfer will enhance Lifecore's capacity and broaden its customer base. Additionally, Lifecore signed a pre-clinical formulation development agreement with an early-stage biotech firm, further expanding its growth pipeline.
Read more →LFCRLifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
Lifecore Biomedical and PolyPeptide Laboratories have announced a collaboration to provide an integrated solution for peptide-based pharmaceuticals in the U.S. This partnership aims to enhance the manufacturing process by combining Lifecore's expertise in formulation and packaging with PolyPeptide's manufacturing capabilities. The goal is to reduce development costs and risks while ensuring regulatory compliance.
Read more →LFCRLifecore Biomedical to Participate at Upcoming Industry Conferences and Events
Lifecore Biomedical, Inc. has announced its participation in three upcoming industry events. The company, known for its expertise in contract development and manufacturing, aims to connect with potential partners and showcase its capabilities in sterile injectable products. This engagement highlights Lifecore's commitment to the biopharmaceutical sector.
Read more →LFCRLIFECORE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Lifecore Biomedical, Inc. and Encourages Long-Term Investors to Contact the Firm – LFCR
Kaskela Law LLC has announced an investigation into Lifecore Biomedical, Inc. for potential breach of fiduciary duty claims. This comes in light of a securities fraud complaint alleging that Lifecore's executives failed to disclose significant internal control deficiencies, leading to material misstatements in financial reporting. Following disclosures about these issues, Lifecore's stock saw a notable decrease in value. The investigation will examine whether the company's board violated securities laws or their fiduciary duties.
Read more →LFCRLIFECORE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating LifeCore Biomedical, Inc. on behalf of long-term stockholders following a class action complaint that alleges the company made false and misleading statements about its business and operations. The investigation focuses on potential breaches of fiduciary duties by the board of directors. Key allegations include deficiencies in internal financial controls, ineffective remediation efforts, and inaccurate financial statements that may have misled investors. Long-term stockholders are encouraged to contact the law firm for further information regarding their rights and potential claims.
Read more →LFCR▼ -5.2%on this news
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference
Lifecore Biomedical will participate as a Gold Sponsor at the 24th Annual Contract Pharma Contracting and Outsourcing Conference on September 18-19, 2025. The event is significant for pharmaceutical outsourcing and contract manufacturing. Lifecore aims to showcase its injectables development expertise and engage with potential customers. The company is focused on expanding its growth strategy and enhancing its market presence.
Read more →LFCRLIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
LifeCore Biomedical, Inc. is under investigation by Bragar Eagel & Squire, P.C. on behalf of long-term stockholders due to a class action complaint filed on July 29, 2024. The complaint alleges that the company made materially false and misleading statements about its financial conditions and operations during the class period from October 7, 2020, to March 19, 2024. Concerns raised include deficient internal controls over financial reporting and the ineffective remediation efforts afterward. Affected investors are encouraged to contact the law firm for further assistance regarding their rights.
Read more →LFCR▲ +5.7%on this newsshared move
lfcrpresentation August 2025 2 Important Information Regarding Forward-Looking Statements This presentation includes forward-looking statements regarding future events and our future results that are subject to the safe
Lifecore has presented forward-looking statements about its growth strategy and financial projections, aiming for over 12% revenue CAGR and adjusted EBITDA margins exceeding 25%. The company experienced a successful transition year in 2025, enhancing its financial position and business development resources. However, it recognizes the inherent risks and uncertainties affecting its operations, including customer funding and regulatory approval challenges, which could impact future performance.
Read more →LFCRLifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update -- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance Maintains Commitment to Mid-Te
Lifecore Biomedical reported its financial results for the fourth quarter and fiscal year 2025, achieving $128.9 million in revenue, which meets its full-year guidance. The company executed nine new customer programs, indicating growth beyond its traditional ophthalmic therapeutics sector. Efficiency improvements have been made under new leadership, contributing to the overall operational productivity. However, the fourth quarter revealed a 4% revenue decline compared to the previous year, influenced by lower CDMO revenues, leading to a net loss of $1.1 million.
Read more →LFCRLifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025
Lifecore Biomedical, Inc. will report its financial results for the fourth quarter and fiscal year 2025 on August 7, 2025, after market close. Following the report, a webcast will be hosted by senior management at 4:30 p.m. Eastern Time to discuss the results. Interested parties can access both the live and archived versions of the webcast on Lifecore's website. As a contract development and manufacturing organization, Lifecore specializes in sterile injectable products and has over 40 years of expertise in the biotech sector.
Read more →LFCRLifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer
Lifecore Biomedical, Inc. has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer, focusing on a novel ophthalmic therapeutic. This agreement is a significant step in Lifecore's growth strategy, allowing it to recognize commercial manufacturing revenue while supporting its customer in advancing their product towards market approval. Alongside the agreement, Lifecore has also initiated a multi-million-dollar project for fill and finish services to enhance the development of the drug candidate.
Read more →LFCRLifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
Lifecore Biomedical has announced the receipt of the remaining $10 million from the sale of its excess high-speed isolator filler, ahead of the previously agreed payment schedule. This early payment strengthens the company's financial position and reflects its disciplined capital management approach. Additionally, Lifecore recently installed a new high-speed filler that is expected to enhance its revenue-generating capabilities significantly. The strategic focus remains on optimizing operations and delivering value to customers and shareholders.
Read more →LFCRLifecore Biomedical Names Mark DaFonseca Chief Commercial Officer
Lifecore Biomedical has appointed Mark DaFonseca as chief commercial officer, bringing nearly 30 years of pharmaceutical experience. DaFonseca will lead the sales organization under a three-pronged growth strategy focused on enhancing Lifecore's brand and expanding customer collaborations. His prior roles in prominent CDMO companies highlight his success in sales and business development. The appointment reflects Lifecore's commitment to strengthen its market position in the CDMO sector.
Read more →LFCRLifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
Lifecore Biomedical, Inc. will participate in the CDMO Live 2025 conference scheduled for May 7-8, 2025, in Rotterdam, Netherlands. Executive Vice President Jackie Klecker will chair a discussion on improving quality management within CDMO partnerships. The event aims to address how quality can drive success in the biopharma outsourcing industry. Lifecore, a fully integrated contract development and manufacturing organization, specializes in sterile injectable pharmaceutical products.
Read more →LFCR▲ +6%on this newsshared move
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer
Lifecore Biomedical has appointed Thomas D. Salus as its Chief Legal and Administration Officer. Salus, who has over 30 years of legal and management experience within the life sciences sector, will oversee all legal activities, human resources, and play a significant role in strategic development for the company. This appointment is part of Lifecore's efforts to enhance its leadership team and streamline operations related to corporate governance and SEC compliance. Salus previously served as general counsel for Viatris and is expected to apply his extensive experience to help drive Lifecore's growth strategies forward.
Read more →LFCR▼ -5.4%on this news· ran to -28% by day 3
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update -- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 -- -- Signed Multiple Development Agreements with New and Exi
Lifecore Biomedical reported its financial results for Q3 of fiscal 2025, showing revenues of $35.2 million and a net loss of $14.8 million. Despite a 2% decrease in revenues from the prior year, the company signed multiple development agreements and increased its cash balance through the sale of unused equipment. Management remains optimistic about achieving future profitability, although operational challenges led to a significant net loss compared to the previous year.
Read more →LFCRLifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025
Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced that it will release its financial results for the third quarter of fiscal year 2025 on April 3, 2025, after market closure. Senior management will host a webcast at 4:30 p.m. Eastern Time to discuss the results and review recent developments within the organization. The live webcast will also be accessible for 30 days on the company’s website, indicating Lifecore's commitment to transparency with investors.
Read more →LFCRLifecore Biomedical to Participate in Upcoming Investor and Industry Conferences
Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced its participation in several upcoming investor and industry conferences, showcasing its commitment to engaging with the investment community. CEO Paul Josephs will deliver a corporate presentation and participate in various investor meetings at the TD Cowen Health Care Conference in Boston, while also joining a fireside chat at the KeyBanc Capital Markets Healthcare Forum in New York. These events aim to strengthen relationships with current and prospective customers, emphasizing Lifecore's experience in contract development and manufacturing for sterile injectable products.
Read more →LFCRLifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference
Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced its participation in the 2025 BIO CEO & Investor Conference, set to take place on February 10-11, 2025, in New York. Company executives, including CEO Paul Josephs and CFO Ryan Lake, will engage in one-on-one meetings during the event. Lifecore is known for its integrated contract development and manufacturing services, particularly for sterile injectable pharmaceutical products, and has over 40 years of industry experience.
Read more →LFCRLifecore Biomedical Announces Special Stockholder Meeting Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Pref
Lifecore Biomedical has announced a special stockholder meeting on April 10, 2025, to seek approval for a proposal to eliminate the cap on the conversion of its Series A Convertible Preferred Stock into common shares. Currently, this cap restricts conversion to 19.99% of outstanding common stock, and the proposed change aims to enhance stockholder value by permitting greater conversion flexibility. While no conversions have occurred so far, the board believes that enhancing capital access is beneficial. The proposal is subject to stockholder approval and SEC guidelines, and Lifecore does not currently plan to seek additional equity capital.
Read more →LFCR▼ -14%on this news
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
Lifecore Biomedical (LFCR) announced the sale of an unused high-speed 10-head isolator filler for $17 million, enhancing its financial position. The company has recently installed a 5-head filler, effectively doubling its capacity to generate up to $300 million in annual revenue. This strategic decision reflects Lifecore's focus on right-sizing operations and streamlining capital expenditures to align with growth objectives. Future payments from the sale will be received in tranches over the next 18 months.
Read more →LFCR▼ -14%on this news
Document Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million Company Believes it is Well Positioned for Mid-Term and Long-Term Growth as Current Capacity Co
Lifecore Biomedical, Inc. has announced a $17 million sale of previously purchased excess capital equipment, strengthening its financial standing. The company expects this move to align with its growth strategy, supporting its projected capacity for generating up to $300 million in annual revenue. With recent installations of a high-speed, multi-purpose 5-head filler, Lifecore aims to enhance service offerings and efficiency moving forward.
Read more →LFCR▼ -9.8%on this news· ran to -22% by day 1shared move
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference
Lifecore Biomedical, Inc. (NASDAQ: LFCR) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco, California. The company's CEO, Paul Josephs, and CFO, Ryan Lake, will engage in one-on-one meetings during the event. This participation underscores Lifecore's role as a key player in contract development and manufacturing within the biopharma sector.
Read more →LFCR▼ -10.4%on this news· ran to -20% by day 3shared move
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update -- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Custom
Lifecore Biomedical reported its financial results for the second quarter of fiscal 2025, with revenues reaching $32.6 million, reflecting an 8% increase from the previous year. The company announced the signing of multiple new customer agreements and improvements to its financial standing through a $24.3 million financing. However, it also recorded a net loss of $6.6 million for the quarter, contrasting sharply with a previous net income of $14.2 million in the same period last year. Additionally, the company experienced increased operating expenses, particularly in selling and administrative costs.
Read more →LFCRLifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
Lifecore Biomedical, a contract development and manufacturing organization, has been chosen by Nirsum Labs to provide CDMO services for the clinical development of NRS-033, a novel treatment for opioid use disorder and alcohol use disorder. The agreement involves technology transfer and process assessment to enhance the fill and finish process. This partnership aims to improve therapeutic retention for patients facing addiction challenges. Nirsum's development program for NRS-033 is supported by funding from the NIH.
Read more →LFCRLifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
Lifecore Biomedical, Inc. has announced it will report its financial results for the second quarter of fiscal year 2025 on January 2, 2025, after market close. A webcast hosted by senior management will take place at 4:30 p.m. Eastern Time on the same day to discuss the results and recent corporate developments. Lifecore is known for its capabilities in contract development and manufacturing, particularly in the area of sterile injectable pharmaceutical products.
Read more →LFCRLifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
Lifecore Biomedical has announced a three-year extension and amendment of its revolving credit facility with BMO, which simplifies terms and reduces interest rates. This move, alongside a recent $24.3 million PIPE financing, has significantly strengthened the company's financial position. Additionally, Lifecore is actively implementing strategies to enhance operational capabilities, including new management appointments and expanded manufacturing capacity, positioning itself for growth in the contract development and manufacturing sector. The partnership with BMO reflects confidence in Lifecore's business and growth strategy.
Read more →LFCR▼ -6.7%on this newsshared move
Lifecore Biomedical Hosts Virtual Investor Day
Lifecore Biomedical, Inc. hosted a virtual investor day, during which its senior management discussed the company's business strategies and future growth plans. The event took place prior to market opening and aimed to engage investors effectively. Lifecore's expertise in the development and manufacturing of sterile injectable pharmaceutical products was highlighted, showcasing its commitment to the biopharmaceutical field.
Read more →LFCR▲ +7.3%on this news
Lifecore Biomedical to Present at Stephens Annual Investment Conference
Lifecore Biomedical, Inc. has announced that CEO Paul Josephs will be a featured speaker at the upcoming Stephens Annual Investment Conference, taking place from November 19-21, 2024, in Nashville, Tennessee. The event will include a fireside chat and provide opportunities for management to engage in one-on-one meetings with investors. Lifecore Biomedical is recognized for its expertise in the development and manufacturing of sterile injectable pharmaceutical products and its leadership in the contract development and manufacturing sector.
Read more →LFCRLifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024
Lifecore Biomedical, Inc. has announced a virtual investor day scheduled for November 21, 2024, before the market opens. The session will run from 8:00 to 9:30 a.m. Eastern Time and will be available via webcast. During this event, senior management will discuss the company's business and strategies for growth. Lifecore, a contract development and manufacturing organization, specializes in the production of sterile injectable pharmaceutical products.
Read more →LFCRLifecore Biomedical Appoints Thomas Guldager as Vice President, Operations
Lifecore Biomedical has appointed Thomas Guldager as Vice President of Operations and Jackie Klecker as Executive Vice President of Quality and Development Services. This strategic bifurcation of operations and quality functions reflects Lifecore's growth strategy and aims to enhance productivity while maintaining high-quality manufacturing standards. Both leaders bring extensive industry experience to their roles, with a focus on improving operational efficiencies and regulatory compliance. The changes come as Lifecore prepares for significant expansion in its manufacturing capacity.
Read more →LFCR▲ +14.3%on this news
lfcrq1fy25ear Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update -- Recorded Revenues of $24.7 million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreement
Lifecore Biomedical has announced its financial results for the first quarter of fiscal 2025, reporting revenues of $24.7 million, a slight increase compared to the previous year. The company has significantly enhanced its operational capacity with the installation of a new 5-head isolator filler, increasing its annual revenue potential to approximately $300 million. Additionally, Lifecore successfully secured $24.3 million in financing, which is expected to support its growth strategy. The company also signed multiple new agreements, reflecting solid business development activity.
Read more →LFCR▲ +14.3%on this news
Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock
Lifecore Biomedical has successfully closed a $24.3 million private placement of its common stock, issuing 5,928,775 shares at a price of $4.10 per share. The company's management expressed optimism regarding shareholder support, which they believe aligns with their growth strategy in the expanding market. The funds raised will be allocated for working capital, operations, and general corporate purposes.
Read more →LFCR▲ +14.3%on this news
Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update
Lifecore Biomedical reported its financial results for the first quarter of fiscal 2025, highlighting revenues of $24.7 million. The company has significantly increased its production capacity with a newly installed 5-head isolator filler, potentially allowing for revenue generation of up to $300 million annually. Lifecore also successfully completed a private placement raising around $24.3 million, enhancing its liquidity for future growth. Additionally, the company signed multiple new business agreements and regained compliance with Nasdaq listing requirements.
Read more →LFCR▼ -5.3%on this newsshared move
Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024
Lifecore Biomedical, Inc. has announced that it will report its financial results for the first quarter of fiscal year 2025 on October 4, 2024. The results will be released prior to market opening, followed by a webcast at 8:30 a.m. Eastern Time where the senior management team will discuss the findings and recent corporate developments. As a contract development and manufacturing organization, Lifecore specializes in sterile injectable pharmaceutical products.
Read more →LFCRLifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology
Lifecore Biomedical has been selected by Lindy Biosciences to provide contract development and manufacturing services for their innovative microglassification technology. This multi-year agreement establishes Lifecore as Lindy Biosciences' preferred CDMO, with expectations of generating over $5 million in revenue. The collaboration will streamline formulation processes and enable the self-administration of biologic therapies, enhancing patient convenience. Lifecore's expertise will be pivotal in supporting this next-generation biotherapeutic formulation development.
Read more →LFCRLifecore Biomedical, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 27, 2024 Deadline to file Lead Plaintiff Motion
Lifecore Biomedical, Inc. is under investigation as the Portnoy Law Firm announces a class action lawsuit for investors who purchased securities between October 7, 2020, and March 19, 2024. The lawsuit alleges that Lifecore made false or misleading statements regarding its financial reporting controls, which led to the issuance of inaccurate financial statements. Investors are urged to contact the law firm for a complimentary case evaluation and to discuss filing a lead plaintiff motion before the September 27, 2024 deadline.
Read more →LFCR▲ +8.1%on this newsshared move
Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational
Lifecore Biomedical has successfully installed and qualified a high-speed, multi-purpose 5-head isolator filler, now GMP-ready and operational. This technology significantly enhances the company's ability to provide fill/finish services for prefilled syringes, vials, and cartridges, effectively more than doubling their capacity. The new filler addresses industry standards for increased safety and quality, supporting a diverse range of product types including both complex and simpler formulations. Lifecore anticipates strong interest from both new and existing clients in leveraging this new capacity.
Read more →LFCRLIFECORE BIOMEDICAL, INC. (NASDAQ: LFCR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Lifecore Biomedical, Inc. Investors of Upcoming Deadline
A class action lawsuit has been filed against Lifecore Biomedical, Inc. (LFCR) alleging violations of the Securities Exchange Act due to inadequate financial reporting. Investors who acquired shares between October 7, 2020, and March 19, 2024, may be eligible to participate in the lawsuit if they file a lead plaintiff motion by September 27, 2024. The firm Bernstein Liebhard LLP is managing the case and aims to recover losses for affected shareholders.
Read more →LFCR▲ +5.6%on this newsshared move
Lifecore Biomedical Regains Compliance with Nasdaq Listing Requirements
Lifecore Biomedical, Inc. has announced that it has regained compliance with Nasdaq's listing requirements, as confirmed by a written notice from the Nasdaq Listing Qualifications Department. This compliance signifies that Lifecore has addressed its financial reporting obligations and has resolved its annual meeting deficiency. However, the company will remain under a Mandatory Panel Monitor until September 2025, and any future non-compliance could result in immediate delisting actions without the opportunity for a cure.
Read more →LFCR▲ +5.6%on this newsshared move
Lifecore Biomedical to Participate in Craig-Hallum Bioprocessing Conference
Lifecore Biomedical, Inc. has announced its participation in the Craig-Hallum Bioprocessing Conference, where CEO Paul Josephs and CFO Ryan Lake will speak. The virtual conference is scheduled for September 19, 2024, and will feature a fireside chat as well as 1-on-1 meetings. Following the event, a webcast replay will be available on the company's investor website. Lifecore is recognized for its expertise in contract development and manufacturing for injectable pharmaceutical products.
Read more →LFCRLifecore Biomedical Appoints Brikkelle Thompson as Senior Vice President of Human Resources
Lifecore Biomedical has appointed Brikkelle Thompson as the new senior vice president of human resources. Thompson brings extensive experience, having worked nearly 25 years in human resources leadership within the medical technology and healthcare sectors. Her role will focus on enhancing Lifecore's company culture and securing top talent essential for the company's growth strategy. CEO Paul Josephs expressed confidence in her ability to align their mission and values with organizational performance.
Read more →LFCRLifecore Biomedical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical has announced the granting of a restricted stock unit (RSU) award and a performance stock unit (PSU) award totaling up to 1,012,500 shares to its new chief financial officer, Ryan D. Lake. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as part of Mr. Lake's employment agreement. The RSU will vest annually over five years, while the PSU's vesting is contingent upon achieving specific stock performance targets over a five-year period. The company's equity inducement plan was adopted earlier this year to facilitate these awards.
Read more →LFCR▲ +8.5%on this newsshared move
Lifecore Biomedical to Participate in 17th Annual Barrington Research Virtual Fall Investment Conference
Lifecore Biomedical, Inc. (NASDAQ: LFCR) has announced its participation in the 17th Annual Barrington Research Virtual Fall Investment Conference, scheduled for September 12, 2024. During this event, company management will hold one-on-one meetings with investors. This participation highlights Lifecore's commitment to engaging with the investment community and showcasing its expertise in contract development and manufacturing.
Read more →LFCRLifecore Biomedical Announces Chief Financial Officer Transition
Lifecore Biomedical announced the transition of its Chief Financial Officer, John Morberg, who will step down effective September 2, 2024, to pursue other opportunities. Ryan Lake, a seasoned financial executive with extensive experience in the CDMO sector, will take over as CFO starting September 3, 2024. The leadership transition reflects the company's strategic focus on sustaining growth within the competitive contract development and manufacturing landscape. The CEO expressed gratitude to Morberg while emphasizing the excitement around Lake's appointment and the value he brings to Lifecore's vision.
Read more →LFCR▲ +5.7%on this news· ran to -36% by day 3shared move
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
Lifecore Biomedical reported significant financial results for fiscal year 2024, highlighting a revenue increase of 24.2% year-over-year amounting to $128.3 million. The fourth quarter showed a particularly strong performance with a gross profit jump of 122%. However, the company also faced challenges, including a net loss of $7.1 million from continuing operations and a reduction in force to align headcount with business needs. New technology enhancements are anticipated to boost production capacity and open new business opportunities.
Read more →LFCRLIFECORE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Lifecore Biomedical, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Lifecore Biomedical, Inc. for alleged failures in financial reporting and internal controls. The lawsuit covers claims between October 2020 and March 2024, during which the company's share price witnessed a decline. Allegations include inaccurate financial statements that require restatement and ineffective remediation efforts. Investors who acquired shares during the specified period are encouraged to contact the filing law firm for more details.
Read more →LFCRLIFECORE BIOMEDICAL, INC. (NASDAQ: LFCR) INVESTOR ALERT: Investors With Large Losses in Lifecore Biomedical Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Bernstein Liebhard LLP has announced a class action lawsuit on behalf of shareholders of Lifecore Biomedical, Inc. The lawsuit, which encompasses purchases made between October 7, 2020, and March 19, 2024, alleges that Lifecore had deficient internal controls that led to multiple inaccurate financial statements requiring restatement. Affected investors are urged to consider their rights and may contact the law firm for further representation details. Those interested in leading the class have until September 27, 2024, to file necessary papers.
Read more →LFCR▼ -8%on this news
Lifecore Biomedical Announces Cooperation Agreement with 22NW Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board
Lifecore Biomedical has entered a cooperation agreement with 22NW, allowing the addition of four new nominees to its Board of Directors, effective after the 2023 Annual Meeting. This strategic move is aimed at avoiding a proxy fight and focuses on the execution of the company's business plan. The new board members bring extensive experience and are expected to contribute positively to governance. The agreement reflects a commitment to enhancing stakeholder value and improving corporate governance practices.
Read more →LFCRLifecore Biomedical Completes Incremental Liquidity Initiatives
Lifecore Biomedical has implemented a series of incremental liquidity initiatives, enhancing its financial resources by approximately $18.5 million. These measures include a prepayment of $5.5 million from a contract manufacturing agreement and an amendment to its ABL Loan Agreement, which introduces additional loan capacity. However, the company's subsidiary, Curation Foods, is undergoing liquidation, and concerns about rising interest expenses have been raised. Lifecore aims to address regulatory compliance and improve its market position in the evolving economic landscape.
Read more →LFCR▲ +5.9%on this news
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
Lifecore Biomedical, Inc. received a notification from Nasdaq regarding its delayed Quarterly Reports, indicating non-compliance with listing requirements. The company must file its reports to avoid potential delisting. While the company has appealed a previous delisting determination, uncertainty remains as the Nasdaq Hearings Panel has yet to render its decision. Lifecore is actively seeking to complete its filings as quickly as possible, but there are no guarantees about meeting compliance deadlines.
Read more →LFCR▲ +9%on this news
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress
Lifecore Biomedical provided a comprehensive business update detailing its financial performance and strategic outlook for fiscal 2024. The company reported solid year-to-date results consistent with prior expectations, highlighting ongoing commercial momentum and significant capacity expansion efforts. Lifecore anticipates a tripling of its theoretical aseptic production capacity in the next few years, supporting a diverse and growing development portfolio. Additionally, it noted improvements in liquidity and operational management, reinforcing the company’s stability in a challenging industry environment.
Read more →LFCRLifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update
Lifecore Biomedical, Inc. has announced that its current auditor, Ernst & Young LLP, will not stand for reappointment for the fiscal year ending May 26, 2024. The company's board of directors is in the process of searching for a replacement auditor. Additionally, Lifecore is planning to provide a business update on April 1, 2024, which is expected to include select financial data and information regarding its commercial activities.
Read more →LFCRLIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating Lifecore Biomedical, Inc. on Behalf of Lifecore Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation into Lifecore Biomedical, Inc. on behalf of its stockholders regarding potential violations of federal securities laws and other unlawful business practices. This follows the company's recent filing of its Annual Report on Form 10-K, which revealed restatements of financial statements due to errors in various calculations. Following the announcement, Lifecore's share price plummeted by over 30%, indicating a significant loss for investors. Shareholders who have suffered losses are encouraged to reach out for participation in the investigative action.
Read more →LFCR▼ -30.3%on this newsshared move
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
Lifecore Biomedical has concluded its strategic evaluation, deciding to pursue a stand-alone growth strategy and appointing Paul Josephs as the new CEO from May 20, 2024, following the retirement of James Hall. The Board believes this approach will optimize shareholder value, particularly through recent investments to expand aseptic production capacity and new product commercialization. The company aims to triple its annual production capacity by fiscal year 2027. Additionally, there will be changes to the Board of Directors with Katrina Houde named Chairperson.
Read more →LFCR▼ -30.3%on this newsshared move
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023
Lifecore Biomedical announced the completion of its Annual Report on Form 10-K for the fiscal year 2023, which includes restatements of prior financial statements due to discrepancies in capitalized interest and inventory valuation. The restatements affect the company's financial metrics from previous years, particularly in inventory and revenue recognition. The company also provided supplemental financial data to help investors analyze the restated figures. This development comes amid ongoing discussions about future compliance with SEC and Nasdaq requirements.
Read more →LFCRLifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
Lifecore Biomedical, Inc. received a Nasdaq notice of delisting due to non-compliance with financial reporting requirements. The company failed to file its Annual Report and several Quarterly Reports by the deadline. Lifecore intends to appeal this decision before a Nasdaq Hearing Panel to delay potential delisting. They are actively working to rectify their financial report filings but acknowledge the uncertainty of meeting compliance requirements or receiving favorable outcomes from the appeal process.
Read more →LFCR▲ +12.5%on this news
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
Lifecore Biomedical has announced a series of updated commercial agreements with its long-term customer Alcon, which include an 8-year extension to their manufacturing agreement and additional provisions for Hyaluronic Acid supply. The company has also received waivers related to its reporting obligations concerning its term debt facility. While these agreements enhance Lifecore's relationship with Alcon, they come amid an ongoing review of strategic alternatives, and the company has postponed the filing of its annual report. The outcome of this strategic review remains uncertain.
Read more →LFCRLifecore Biomedical Provides Business Update
Lifecore Biomedical, Inc. (NASDAQ: LFCR) has provided a business update highlighting its progress towards filing its Annual Report on Form 10-K, including necessary restatements. The company has active development projects, totaling 32, and continues to work on enhancing its manufacturing capabilities. Additionally, Lifecore is in the process of evaluating strategic alternatives, although there is no guaranteed timeline or outcome for any potential transactions.
Read more →LFCRLifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report
Lifecore Biomedical, Inc. received a notice from Nasdaq indicating that the company is not in compliance due to delays in filing its Interim Report on Form 10-Q and its Annual Report on Form 10-K. The notice does not affect the current listing or trading of Lifecore's securities. In response, the company has submitted a plan to regain compliance that is currently under review by Nasdaq. If accepted, Lifecore may have up to 180 days to file the necessary reports to comply with Nasdaq regulations.
Read more →LFCR▲ +7.8%on this news
Lifecore Biomedical Provides Update for Development Portfolio and Timing of Delayed Filings
Lifecore Biomedical provided an update on its development portfolio and the timing of delayed filings. The company has added two projects, bringing its total to 31 and has increased its development pipeline to 58 projects. However, it is facing delays in filing its Annual Report and Quarterly Report due to complications arising from recent corporate transactions. Lifecore also expressed confidence in its financial resources to support operations through fiscal 2024, despite these reporting delays.
Read more →LFCR▼ -11.8%on this news
Lifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 Results
Lifecore Biomedical reported its fourth quarter and full fiscal year 2023 results, marking a complex financial landscape. The company saw a 12.2% increase in revenues for Q4, but experienced a significant net loss of $33.8 million, a substantial rise from the prior year's loss. While Lifecore is expanding its development portfolio and production capacity, its overall financial performance shows signs of struggle with decreased gross profits and a year-over-year revenue decline for the full fiscal year.
Read more →LFCRLifecore Biomedical Sets Fourth Quarter 2023 Earnings Conference Call for August 31, 2023 at 7:30 a.m. CT
Lifecore Biomedical, a contract development and manufacturing organization, will host a conference call on August 31, 2023, at 7:30 a.m. CT to discuss its fiscal fourth quarter financial results. The call will be accessible via Lifecore’s website, and a replay will be available for a limited time post-event. The company specializes in sterile injectable products and has significant experience in supporting biopharmaceutical innovations.
Read more →LFCRLifecore Biomedical Reports Third Quarter Fiscal Year 2023 Results
Lifecore Biomedical reported its fiscal third quarter results, with notable changes including a long-term supply agreement with Alcon and restructuring of debt arrangements. Although the company faced a decline in revenues and profit, it also removed its going concern qualification. The CEO highlighted advancements in the commercial development pipeline and expectations of improved financial performance in the upcoming quarter, projecting a doubling of adjusted EBITDA. Lifecore continues its evolution as a CDMO following divestments of its Curation Foods segment.
Read more →LFCR▲ +50.2%on this news
expressions are used to identify forward-looking statements. Forward-looking statements in this press release include statements, among others, related to the Company's exploration of its strategic alternatives, the futu
Lifecore Biomedical has entered a $150 million financing agreement, allowing it to repay existing loans and enhance its operational capacity. The company has expanded its supply agreement with Alcon, significantly increasing the amount of hyaluronic acid it will supply over the next decade. This strategic move aims to solidify Lifecore's position and explore further business alternatives to maximize value for stockholders. The financing arrangement includes favorable repayment terms and the leaseback of fermentation equipment, positioning Lifecore for future growth.
Read more →LFCRLifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer
Lifecore Biomedical has secured $150 million in financing from Alcon, enabling the repayment of existing term loans and expanding its hyaluronic acid supply agreement. The new agreement with Alcon will last until December 31, 2033, significantly increasing the amount of HA Lifecore is expected to supply. This arrangement is intended to strengthen the partnership with Alcon while also enhancing Lifecore's operational capabilities and financial positioning.
Read more →LFCRLifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT
Lifecore Biomedical, a contract development and manufacturing organization, has scheduled a conference call for June 1, 2023, at 7:30 a.m. CT to discuss its fiscal 2023 third quarter financial results. Participants can join via a webcast accessible through Lifecore's website, which will remain available for 30 days. Interested parties can also dial in by telephone, with a replay option available shortly after the call.
Read more →LFCRLifecore Biomedical Announces Sale of Curation Foods’ O Olive Oil and Vinegar Business
Lifecore Biomedical has finalized the sale of its Curation Foods’ O Olive Oil and Vinegar business for $6.23 million. This sale marks the completion of the monetization effort of all remaining assets from Curation Foods. CEO James G. Hall expressed optimism about this strategic move, stating it would allow the company to focus on its core operations and long-term growth. The sale proceeds will be utilized to reduce existing borrowings, freeing up resources for Lifecore's development portfolio.
Read more →LFCRLifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship
Lifecore Biomedical has signed a term sheet with a long-time commercial customer to enhance their existing contract development and manufacturing relationship. The agreement includes a $10 million upfront cash commitment to prepare for increased production capacity, along with up to $15 million in capital reimbursement for equipment purchases. Lifecore anticipates negotiating a multi-year amendment to extend this partnership, aiming to increase efficiency and support the customer's product portfolio. The deal represents a significant opportunity for Lifecore to strengthen its operational capabilities and customer service.
Read more →LFCRLifecore Biomedical Announces Intent to Explore Strategic Alternatives
Lifecore Biomedical has announced its intention to explore strategic alternatives to enhance value for its stockholders. The Board plans to assess various options, including potential sales or financing transactions, with the support of financial and legal advisors. The strategic review process will begin only after securing a forbearance agreement from its lenders, which is essential for facilitating the review. No definite timeline has been set, and there is no assurance regarding the success of this process.
Read more →LFCRLifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results
Lifecore Biomedical reported disappointing second quarter results for fiscal year 2023, with a net loss of $12.4 million and a 10.7% decrease in revenue compared to the previous year. The company announced its intention to explore strategic alternatives, potentially exploring a sale or other financial transactions to maximize shareholder value. Despite these challenges, Lifecore expanded its development pipeline and has transitioned three projects to commercialization with FDA approval.
Read more →LFCRLifecore Biomedical Announces Sale of Curation Foods’ Avocado Products Business
Lifecore Biomedical has completed the sale of its Curation Foods’ avocado products business for $17.5 million in cash. This transaction is part of their strategy to monetize remaining Curation Foods assets and enhance focus on Lifecore as a standalone contract development and manufacturing organization. The proceeds will assist in repaying borrowings, further strengthening the company's financial position. The avocado products business will be classified as discontinued operations starting in the fiscal third quarter of 2023.
Read more →LFCR▲ +9.3%on this news
Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report
Lifecore Biomedical received a notice from Nasdaq for failing to timely file its Quarterly Report on Form 10-Q for the quarter ended November 27, 2022. The notice does not immediately affect the company's stock listing or trading but requires them to submit a compliance plan within 60 days. If accepted, Lifecore may have up to 180 additional days to file the overdue report. The company is actively working on completing and filing the 10-Q to regain compliance.
Read more →LFCRLifecore Biomedical Raises Capital with Private Placement of Convertible Preferred Stock; Amends Credit Facilities
Lifecore Biomedical has successfully raised $38.75 million through the issuance of Series A convertible preferred stock, aimed at enhancing its working capital and addressing strong market demand for its products. The company has also amended its credit facilities to increase liquidity and alleviate financial covenants. Additionally, two new directors have been appointed to the board, signaling a strategic shift as Lifecore focuses on its core competencies while pursuing an ongoing divestment process of non-CDMO assets. This capital infusion and restructuring are intended to support Lifecore's growth ambitions in the biotech industry.
Read more →LFCRLifecore Biomedical Raises Capital for Growth with Existing Stockholder
CHASKA, Minn., Nov. 25, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced the closing of a $5 million private placement (“PIPE”) of its common stock wi
Read more →LFCRLifecore Biomedical Announces Completion of Corporate Name Change
Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol “LFCR” Lifecore global headquarters relocated to Chaska, MN Launches new investor relations website: ir.lifecore.com CHASKA, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Life
Read more →LFCRLifecore Biomedical to Participate in the Stephens Annual Investment Conference on Thursday, November 17, 2022
CHASKA, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Lifecore” or the “Company”), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. (“Lifecore”) and Curation Foods, Inc. (“Curation Foods”), – today a
Read more →LFCRInformation Investor Relations Jeff Sonnek (646) 277-1263 jeff.sonnek icrinc.com Landec Corporation Announces Intention to Become Lifecore Biomedical Landec expected to rename and rebrand to
jeff.sonnek icrinc.com Landec Corporation Announces Intention to Become Lifecore Biomedical Landec expected to rename and rebrand to Lifecore Biomedical and update Nasdaq ticker symbol Announces future changes to its Board of Directors SANTA MARIA, CA MINNEAPOLIS, MN - August
Read more →LFCRLifecore to Manufacture New Innovative Drug for Treatment of Postoperative Pain Following Customer’s FDA Approval
CHASKA, Minn., May 17, 2021 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc., a fully-owned subsidiary of Landec Corporation (Nasdaq: LNDC), today announced the receipt by Heron Therapeutics (“Heron”), one of Lifecore’s customers, of U.S. Food and Drug Administration (FDA) approval
Read more →LFCRLandec Corporation Mourns the Passing of Board Member Charles Macaluso
Landec Corporation Mourns the Passing of Board Member Charles Macaluso SANTA MARIA, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- It is with great sadness that the Landec Corporation (Nasdaq LNDC) announces the death of board member Charles "Mac" Macaluso who passed away on February
Read more →LFCRLandec Appoints New Chief Financial Officer
Landec Appoints New Chief Financial Officer SANTA MARIA, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq LNDC), a diversified health and wellness company with two operating businesses, Curation Foods, Inc. and Lifecore Biomedical, Inc., today announced the a
Read more →LFCRAs a result of refinancing the Company's existing credit facilities with these new credit facilities, in the third quarter of fiscal 2021, Landec expects to record a $1.2 million charge, primarily as a result of the non-
jeff.sonnek icrinc.com Landec Corporation Announces Comprehensive Refinancing of Credit Facilities SANTA MARIA, Calif., - January 4, 2021 - Landec Corporation (Nasdaq LNDC) (the "Company"), a diversified health and wellness company with two operating businesses, Curation Foods,
Read more →LFCRLandec Continues Progression of Transformation Plan for Curation Foods, Announcing Agreement to Divest Hanover Manufacturing Operations
Landec Continues Progression of Transformation Plan for Curation Foods, Announcing Agreement to Divest Hanover Manufacturing Operations SANTA MARIA, Calif., August 25, 2020 -- Landec Corporation (Nasdaq LNDC) ("Landec" or the "Company"), a diversified health and wellness Company
Read more →LFCRLandec Nominates Three New Members to its Board of Directors, Providing Deep Expertise to Both Business Segments
Landec Nominates Three New Members to its Board of Directors, Providing Deep Expertise to Both Business Segments SANTA MARIA, Calif., August 24, 2020 -- Landec Corporation (Nasdaq LNDC) ("Landec" or the "Company"), a diversified health and wellness Company with two operating bu
Read more →LFCRLandec Corporation Amends Credit Agreement
Landec Corporation Amends Credit Agreement SANTA CLARA, CA - July 16, 2020 - Landec Corporation (Nasdaq LNDC) (the "Company"), a diversified health and wellness company with two operating businesses, Curation Foods, Inc. and Lifecore Biomedical, Inc., today announced its entry i
Read more →LFCRLandec Corporation Amends Credit Agreement, Appoints Brian McLaughlin Chief Financial Officer Amendment provides covenant relief McLaughlin named CFO following his service as interim CFO since January 2020
Landec Corporation Amends Credit Agreement, Appoints Brian McLaughlin Chief Financial Officer Amendment provides covenant relief McLaughlin named CFO following his service as interim CFO since January 2020 SANTA CLARA, CA - March 25, 2020 - Landec Corporation (Nasdaq LNDC) ("C
Read more →LFCRInformation: Investor Relations: Jeff Sonnek (646) 277-1263 jeff.sonnek@icrinc.com Landec Corporation Reports Second Quarter and First Half Fiscal 2020 Results
Contact Information: Investor Relations: Jeff Sonnek (646) 277-1263 jeff.sonnek@icrinc.com Landec Corporation Reports Second Quarter and First Half Fiscal 2020 Results SANTA MARIA, CA - January 2, 2020 - Landec Corporation (Nasdaq: LNDC), a diversified health and wellness compa
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Jeff Sonnek Executive Vice President Finance and Administration and CFO (646) 277-1263 (650) 261-3677 Jeff.sonnek@icrinc.c
Contact Information: At the Company: Investor Relations: Gregory S. Skinner Jeff Sonnek Executive Vice President Finance and Administration and CFO (646) 277-1263 (650) 261-3677 Jeff.sonnek@icrinc.com Landec Corporation Reports Fiscal 2020 First Quarter Results Company Advance
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Jeff Sonnek Executive Vice President Finance and CFO (646) 277-1263 (650) 261-3677 Jeff.sonnek@icrinc.com Landec Corporati
Contact Information: At the Company: Investor Relations: Gregory S. Skinner Jeff Sonnek Executive Vice President Finance and CFO (646) 277-1263 (650) 261-3677 Jeff.sonnek@icrinc.com Landec Corporation Reports Fourth Quarter and Fiscal 2019 Results SANTA CLARA, CA - July 30, 20
Read more →LFCRDiversified Health and Wellness Solutions FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner John Mills, Partner Executive Vice President and CFO (646) 277-1254 (650) 261-36
Diversified Health and Wellness Solutions Contact Information: At the Company: Investor Relations: Gregory S. Skinner John Mills, Partner Executive Vice President and CFO (646) 277-1254 (650) 261-3677 John.Mills@ICRINC.com Media Inquiries: Leigh Lehman Current G
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner John Mills, Partner Vice President Finance and CFO (646) 277-1254 (650) 261-3677 John.Mills@ICRINC.com Landec Corporation
Contact Information: At the Company: Investor Relations: Gregory S. Skinner John Mills, Partner Vice President Finance and CFO (646) 277-1254 (650) 261-3677 John.Mills@ICRINC.com Landec Corporation Reports Third Quarter and First Nine Months Fiscal 2019 Results Third Quarter a
Read more →LFCRInformation: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 Investor Relations: John Mills, Partner (646) 277-1254 John.Mills@ICRINC.com Landec Corporation
Contact Information: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 Investor Relations: John Mills, Partner (646) 277-1254 John.Mills@ICRINC.com Landec Corporation Reports Fourth Quarter and Fiscal 2017 Results Lifecore Exceeds Fiscal 2017 Exp
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner John Mills, Partner Vice President Finance and CFO (646) 277-1254 (650) 261-3677 John.Mills@ICRINC.com Landec Corporation Reports Third Quarter
FOR IMMEDIATE RELEASE Exhibit 99.1 At the Company: Investor Relations: Gregory S. Skinner John Mills, Partner Vice President Finance and CFO (646) 277-1254 (650) 261-3677 John.Mills@ICRINC.com Landec Corporation Reports Third Quarter and First Nine Months Fiscal 2017 Results
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Vice President Finance and CFO John Mills, Partner (646) 277-1254 (650) 261-3677 John.Mills@ICRINC.com Landec Corporation
FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner Vice President Finance and CFO John Mills, Partner (646) 277-1254 (650) 261-3677 John.Mills@ICRINC.com Landec Corporation Reports Fiscal Fourth Quarter and Full Year 2016 Results
Read more →LFCRInformation: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 Investor Relations: Matt Glover 949-574-3860 LNDC@liolios.com Landec Corporation Reports Third Q
FOR IMMEDIATE RELEASE Contact Information: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 Investor Relations: Matt Glover 949-574-3860 LNDC@liolios.com Landec Corporation Reports Third Quarter and Nine Months Fiscal 2016 Results Severe Produc
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Matt Glover Vice President Finance and CFO 949-574-3860 (650) 261-3677 LNDC@liolios.com Landec Corporation Reports Second
FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner Matt Glover Vice President Finance and CFO 949-574-3860 (650) 261-3677 LNDC@liolios.com Landec Corporation Reports Second Quarter and First Half Fiscal 2016 Results Severe
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Matt Glover Vice President Finance and CFO (949) 574-3860 (650) 261-3677 LNDC@liolios.com Landec Corporation Reports Fisca
FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner Matt Glover Vice President Finance and CFO (949) 574-3860 (650) 261-3677 LNDC@liolios.com Landec Corporation Reports Fiscal First Quarter 2016 Results Lifecore revenue
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO (949) 574-3860 (650) 261-3677 LNDC@liolios.com Landec Corpor
Contact Information: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO (949) 574-3860 (650) 261-3677 LNDC@liolios.com Landec Corporation Reports Fiscal Fourth Quarter and Full Year 2015 Results Landec's Fiscal
Read more →LFCRFOURTH AMENDMENT TO CREDIT AGREEMENT FOURTH AMENDMENT TO CREDIT AGREEMENT (" Amendment ") dated as of
FOURTH AMENDMENT TO CREDIT AGREEMENT FOURTH AMENDMENT TO CREDIT AGREEMENT ("Amendment") dated as of May 27, 2015, by and among APIO, INC., a Delaware corporation ("Apio"), CAL EX TRADING COMPANY, a Delaware corporation ("Cal Ex"), GREENLINE LOGISTICS, INC., an Ohio corporation (
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO (949) 574-3860 (650) 261-3677 LNDC@liolios.com Landec Secures New Equipment and Re
Contact Information: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO (949) 574-3860 (650) 261-3677 LNDC@liolios.com Landec Secures New Equipment and Real Property Loans To Support Planned Capacity Expansion
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO 949-574-3860 (650) 261-3677 LNDC@liolios.com Landec Corporat
FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO 949-574-3860 (650) 261-3677 LNDC@liolios.com Landec Corporation Reports Third Quarter and First Nine Months of Fiscal
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO (949) 574-3860 (650) 261-3677 LNDC@liolios.com Landec CEO Re
FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO (949) 574-3860 (650) 261-3677 LNDC@liolios.com Landec CEO Retirement Date Delayed Beyond May 2015 MENLO PARK,
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO 949-574-3860 (650) 261-3677 LNDC@liolios.com Landec Makes In
FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO 949-574-3860 (650) 261-3677 LNDC@liolios.com Landec Makes Investment in Windset for Future Expansion MENLO PARK, CA
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 Matt Glover or Michael Koehler (949) 574-3860 LNDC@liolios.com Landec Corpor
FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 Matt Glover or Michael Koehler (949) 574-3860 LNDC@liolios.com Landec Corporation Reports Fiscal First Quarter 2015 Results Apio Foo
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO (949) 574-3860 (650) 261-3677 LNDC@liolios.com Landec CEO to
FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO (949) 574-3860 (650) 261-3677 LNDC@liolios.com Landec CEO to Retire at Fiscal Year-end May 2015 and Remain on Board
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO 949-574-3860 (650) 261-3677 LNDC@liolios.com Landec Increase
FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner Matt Glover or Michael Koehler Vice President Finance and CFO 949-574-3860 (650) 261-3677 LNDC@liolios.com Landec Increases Investment in Windset Landec Also Secures New Equipmen
Read more →LFCRLANDEC CORPORATION 2013 STOCK INCENTIVE PLAN Section 1. INTRODUCTION . 1 The Landec Corporation 2013 Stock Incentive Plan will be effective (the "Effective Date") upon its approval by an affirmative vote of the holders o
2013 STOCK INCENTIVE PLAN Section 1. INTRODUCTION. 1 The Landec Corporation 2013 Stock Incentive Plan will be effective (the "Effective Date") upon its approval by an affirmative vote of the holders of a majority of the Shares that are present in person or by proxy and entitled
Read more →LFCRInformation: At the Company: Investor Relations: Gregory S. Skinner Justin Vaicek Vice President Finance and CFO 949-574-3860 (650) 261-3677 LNDC@liolios.com Landec Corporation Reports Fisca
FOR IMMEDIATE RELEASE Contact Information: At the Company: Investor Relations: Gregory S. Skinner Justin Vaicek Vice President Finance and CFO 949-574-3860 (650) 261-3677 LNDC@liolios.com Landec Corporation Reports Fiscal First Quarter 2014 Results Company Exceeds Revenue Pla
Read more →LFCRInformation: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 Landec Corporation Reports Fiscal Fourth Quarter and Full Year 2013 Results Landec FY 2013 Reven
Contact Information: Vice President Finance and CFO Landec Corporation Reports Fiscal Fourth Quarter and Full Year 2013 Results Landec FY 2013 Revenues Increase 39% to a Record $441.7 Million and EPS to $0.85 MENLO PARK, CA - July 31, 2013 -- Landec Corporation (Nasdaq: LNDC)
Read more →LFCRInformation: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 LANDEC REPORTS RESULTS FOR THIRD QUARTER AND FIRST NINE MONTHS OF FISCAL YEAR 2013
Contact Information: Vice President Finance and CFO LANDEC REPORTS RESULTS FOR THIRD QUARTER AND FIRST NINE MONTHS OF FISCAL YEAR 2013 MENLO PARK, CA March 26, 2013 -- Landec Corporation (Nasdaq: LNDC), today reported results for the third quarter and first nine months of fis
Read more →LFCRInformation: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 LANDEC REPORTS RESULTS FOR SECOND QUARTER AND FIRST HALF FISCAL YEAR 2013 AND INCREASES GUIDANCE
FOR IMMEDIATE RELEASE Contact Information: Vice President Finance and CFO LANDEC REPORTS RESULTS FOR SECOND QUARTER AND FIRST HALF FISCAL YEAR 2013 AND INCREASES GUIDANCE FOR FISCAL YEAR 2013 MENLO PARK, CA - January 2, 2013 -- Landec Corporation (Nasdaq: LNDC), today report
Read more →LFCRInformation: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 LANDEC CORPORATION REPORTS FIRST QUARTER FISCAL YEAR 2013
Contact Information: Vice President Finance and CFO LANDEC CORPORATION REPORTS FIRST QUARTER FISCAL YEAR 2013 RESULTS MENLO PARK, CA - September 26, 2012 -- Landec Corporation (Nasdaq: LNDC) today reported results for the first quarter of fiscal year 2013 ended August 26, 201
Read more →LFCRInformation: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 LANDEC CORPORATION REPORTS FISCAL YEAR 2012 AND FOURTH QUARTER RESULTS Landec reports record rev
Contact Information: Vice President Finance and CFO LANDEC CORPORATION REPORTS FISCAL YEAR 2012 AND FOURTH QUARTER RESULTS Landec reports record revenues for FY 2012 of $317.6 million and EPS of $0.49 MENLO PARK, CA - July 31, 2012 -- Landec Corporation (Nasdaq: LNDC), today
Read more →LFCRInformation: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677
Contact Information: Vice President Finance and CFO LANDEC SELLS SEED COATING BUSINESS AND PARTNERS WITH INCOTEC TO GAIN GLOBAL ACCESS FOR LANDEC AGRICULTURE SEED COATING TECHNOLOGY MENLO PARK, CA - June 26, 2012 -- Landec Corporation (Nasdaq:LNDC), a company that develops and
Read more →LFCRInformation: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 LANDEC CORPORATION ACQUIRES GREENLINE FOODS, INC. MENLO PARK, Calif.--(BUSINESS WIRE)
Contact Information: Vice President Finance and CFO LANDEC CORPORATION ACQUIRES GREENLINE FOODS, INC. MENLO PARK, Calif.--(BUSINESS WIRE)-April 23, 2012--Landec Corporation (Nasdaq:LNDC), a company that develops and markets patented products for food, agricultural and biomedic
Read more →LFCRInformation: At the Company: Gregory S. Skinner Vice President Finance and CFO (650) 261-3677 LANDEC CORPORATION REPORTS THIRD QUARTER AND FIRST NINE MONTHS FISCAL YEAR 2012 RESULTS Landec i
Contact Information: Vice President Finance and CFO LANDEC CORPORATION REPORTS THIRD QUARTER AND FIRST NINE MONTHS FISCAL YEAR 2012 RESULTS Landec increases revenue guidance and guides to top of net income growth for FY 2012 MENLO PARK, CA - March 26, 2012 -- Landec Corporati
Read more →Competitive Position
How LFCR ranks across every disease it competes inCompetitive Position is a premium feature
See how LFCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial